MINI-FUTURE SHORT - ELI LILLY & CO | Real-time Bid/Ask 15:34:52 29/05/2024 BST | ||
| 0.83 CHF / 0.84 CHF | +1.83% |
|
| Current month | -46.75% | ||
| 1 month | -46.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/05/24 | 0.82 | -1.20% |
| 24/05/24 | 0.83 | +2.47% |
| 23/05/24 | 0.81 | -10.99% |
| 22/05/24 | 0.91 | +3.41% |
Delayed Quote Swiss Exchange
Last update May 27, 2024 at 04:20 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYHDU | |
| ISIN | CH1322969135 |
| Date issued | 09/02/2024 |
| Strike | 897.6 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 1.42 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.62 CHF |
|---|---|
| Lowest since issue | 0.81 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.19% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.9
USD
Average target price
850.8
USD
Spread / Average Target
+5.31%
- Stock Market
- Certificates
- LLYHDU Certificat
